Gali Health Launches IBD Footprints Research Program

SAN FRANCISCO--(BUSINESS WIRE)-- Gali Health, a precision medicine company working to develop personalized medicine solutions for chronic diseases, is calling for people affected by inflammatory bowel diseases (IBD) to participate in its IBD Footprints Program. The program is aimed at improving clinical management of IBD, including Crohn’s disease and ulcerative colitis. Participants must be diagnosed with IBD, be over 18 years old and live in the United States.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005170/en/

Mobile health support and tracking technology, combined with mail-in research sample collection, create unprecedented digital, clinical and biological data streams for better IBD diagnostics and therapeutics development. (Photo: Business Wire)

Mobile health support and tracking technology, combined with mail-in research sample collection, create unprecedented digital, clinical and biological data streams for better IBD diagnostics and therapeutics development. (Photo: Business Wire)

To learn more about the program and to sign up, please visit https://galihealth.com/ibd-footprints/

The program aims to create the most comprehensive multi-omic dataset that integrates clinical, lifestyle, and large-scale biological data over time, laying the foundation for novel diagnostics and therapeutics development. Gali Health will leverage state-of-the-art technologies for monitoring participants’ health, sample biobanking, and generating multidimensional sequencing data. This large-scale, longitudinal approach, which involves collecting thousands of samples and patient reported outcomes, provides an unprecedented granular view of individual clinical and molecular differences.

“A personalized medicine approach in oncology has led to the development of targeted therapies that have significantly improved outcomes for cancer patients, and the Gali Health team is uniquely positioned to drive research to advance similar efforts in the field of IBD,” says Mamatha Shekar, Ph.D., the head of genome sciences at Gali Health.

As part of the program, at-home collection kits for stool and saliva samples are mailed to participants who also use the Gali mobile app to record continuous digital health and lifestyle data. Participants will receive personalized digital reports in the Gali app describing their study results.

In the future, the IBD Footprints Program will expand internationally and include collection of other types of biological data.

About Gali Health

Gali Health, Inc. is a San Francisco-based precision medicine company that develops personalized medicine solutions for individuals afflicted by a variety of chronic conditions. Its approach combines Gali, an AI-based personalized health assistant that helps people proactively manage their health, and a “Healthomics” platform that leverages population-level health, lifestyle and genomic information for diagnostic and therapeutic development.

To learn more, please visit https://galihealth.com/precision-medicine/

Contacts

Arielle Radin, Gali Health
Director of Clinical Research
arielle@galihealth.com

 
 

Source: Gali Health, Inc.

Smart Multimedia Gallery

Mobile health support and tracking technology, combined with mail-in research sample collection, create unprecedented digital, clinical and biological data streams for better IBD diagnostics and therapeutics development. (Photo: Business Wire)

Gali Health's personal health assistant mobile app named Gali empowers patients to systematically capture their daily symptoms and lifestyle, track important changes in their health and access personalized education and community support. Gali Health also relies on the Gali app to facilitate the collection and banking of various types of samples for subsequent molecular analysis and biomarker identification as part of its IBD Footprints Program. (Photo: Business Wire)

View this news release and multimedia online at:
http://www.businesswire.com/news/home/20200901005170/en

Back to news